According to business intelligence firm GBI Research, the ADHD medication market will rise in value from $6.9 billion in 2013 to $9.9 billion by 2020, “with broadening diagnostic criteria a key driver of growth,” reports PharmaBiz.com.
The GBI Research report looks at eight major markets (the US, the UK, France, Germany, Spain, Italy, Japan and Canada). Dale Prior of GBI Research tells PharmaBiz.com that, “Debate remains about the fear of under- or over-diagnosis, the causes and legitimacy of ADHD as a condition, and the skew towards greater prevalence in the US.”
Nevertheless, Prior expects market growth “due largely to an increased recognition of adult ADHD” and the broadening of the diagnostic criteria for ADHD in the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders. “These developments herald the final acceptance of adult ADHD in a clinical setting and mean that many people who met the ‘partial remission’ criteria will now meet the full criteria, leading to an increase in diagnosis,” says Prior. “However, the continuing reluctance of many patients to seek treatment for mental health conditions will be a barrier to ADHD diagnosis rates, and consequently to any further market growth.”
GBI Research says ADHD treatment market value to reach $9.9 bn by 2020 (PharmaBiz.com, August 25, 2014)
